Clinical Trial Search

Primary: Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16 — -75.5; -70.5; -67.4; -64.9 Percent change — p=<0.0001

Primary: Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 — 0; 0; 0; 3 Participants

Primary: Overall Survival (OS) — 10.9; 10.7 months — p=0.5157

Primary: Time to Progression (TTP) of the Treated Lesion(s) According to RECIST Criteria

Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants

Primary: Confirmed Tumor Response Rate (Proportion of Participants With Complete Response) — .38 proportion of patients

Primary: Time — 74; 81 minutes

Primary: Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score — -1.6; -1.6 units on a scale — p=0.4503

Primary: Change From Baseline in Mean Menstrual Cramping Pain Score Through Cycle 2 — -1.7; -1.7; -1.9; -1.7 Units on a scale — p=< 0.001

Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…

Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 3; 4; 7; 0 Participants

Primary: Safety Lab Evaluations — -4.0; 0.1; 0.2; 1.1 percentage change from baseline

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy — 28.6 Percentage of…

Primary: Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and…

Primary: Relapse Free Survival — 3 Participants